advanced malignancy
Conditions
Interventions
Group A:the dose of rhTPO is 600U/kg
Group B:the dose of rhTPO is 450U/kg
Group C:the dose of rhTPO is 300U/kg
Sponsors
the third people's hospital of Zhengzhou city
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. For patients with high risk factors of bleeding, the lowest value of platelets after the end of the previous chemotherapy cycle is less than 100x10^9/L or the range of platelets decrease is more than or equal to 50*10^9/L; for those without high risk factors of bleeding, the lowest value of platelets after the end of the previous chemotherapy cycle is less than 75 * 10^9/L or the range of platelets decrease is more than or equal to 50×10^9/L. The high risk factors for bleeding include: (1) Previous bleeding history; (2) Platelet < 75 * 10^9 / L before chemotherapy; (3) Chemotherapy with platinum, gemcitabine, cytarabine, anthracycline and other drugs; (4) Previous radiotherapy, especially for long bone and flat bone (such as pelvis and sternum). 2. Solid tumor patients confirmed by pathology. 3. Willing to participate in the whole research process, follow the research procedure, and give written informed consent before taking any specific steps of the research. 4. The function of heart, liver, lung and kidney is normal. 5. Aged 75-18 years. 6. PS score is 0-2.
Exclusion criteria
Exclusion criteria: 1) The estimated survival time is less than 3 months. 2) Bone marrow infiltration causes thrombocytopenia. 3) Blood disease causes thrombocytopenia. 4) There was a serious disease, which the researchers judged might prevent patients from participating in this study. 5) There was clinical evidence of active bacterial or fungal infection or active viral infection. 6) Poor compliance, unable to participate in the plan setting on time. 7) In the past 12 months, there has been any of the following personal history: syncope due to cardiovascular causes, ventricular tachycardia, ventricular fibrillation or cardiac arrest.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet change range;The rate of patients whose platelets return to normal.; | — |
Countries
China
Contacts
Public ContactChen Lu
The Third People's Hospital of Zhengzhou
Outcome results
None listed